Discerning the Prospects of miRNAs as a Multi-Target Therapeutic and Diagnostic for Alzheimer’s Disease

Bhatnagar, Devyani; Ladhe, Shreya; Kumar, Dileep

doi:10.1007/s12035-023-03446-0

Cited by 15 publications

(2 citation statements)

References 221 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Organoids have not only been developed for AD but have also been cultured for other neurological diseases such as amyotrophic lateral sclerosis, Parkinson’s disease, and Huntington’s disease. Various other types of therapies include the use of gene therapy [ 187 ], mRNA [ 188 ], siRNA [ 189 ], miRNA [ 190 ], and antisense oligonucleotides [ 191 ].…”

Section: Advanced Drug Delivery Systems In Epigeneticsmentioning

confidence: 99%

Epigenetic Alterations in Alzheimer’s Disease: Impact on Insulin Signaling and Advanced Drug Delivery Systems

Greeny,

Nair,

Sadanandan

et al. 2024

Biology

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a neurodegenerative condition that predominantly affects the hippocampus and the entorhinal complex, leading to memory lapse and cognitive impairment. This can have a negative impact on an individual’s behavior, speech, and ability to navigate their surroundings. AD is one of the principal causes of dementia. One of the most accepted theories in AD, the amyloid β (Aβ) hypothesis, assumes that the buildup of the peptide Aβ is the root cause of AD. Impaired insulin signaling in the periphery and central nervous system has been considered to have an effect on the pathophysiology of AD. Further, researchers have shifted their focus to epigenetic mechanisms that are responsible for dysregulating major biochemical pathways and intracellular signaling processes responsible for directly or indirectly causing AD. The prime epigenetic mechanisms encompass DNA methylation, histone modifications, and non-coding RNA, and are majorly responsible for impairing insulin signaling both centrally and peripherally, thus leading to AD. In this review, we provide insights into the major epigenetic mechanisms involved in causing AD, such as DNA methylation and histone deacetylation. We decipher how the mechanisms alter peripheral insulin signaling and brain insulin signaling, leading to AD pathophysiology. In addition, this review also discusses the need for newer drug delivery systems for the targeted delivery of epigenetic drugs and explores targeted drug delivery systems such as nanoparticles, vesicular systems, networks, and other nano formulations in AD. Further, this review also sheds light on the future approaches used for epigenetic drug delivery.

show abstract

Section: Advanced Drug Delivery Systems In Epigeneticsmentioning

confidence: 99%

Epigenetic Alterations in Alzheimer’s Disease: Impact on Insulin Signaling and Advanced Drug Delivery Systems

Greeny,

Nair,

Sadanandan

et al. 2024

Biology

View full text Add to dashboard Cite

show abstract

“…As miRNAs are released from cells into biofluids and tend to be very stable, they serve as promising biomarkers for complex traits. Studies have identified specific miRNAs that are dysregulated in AD patients, suggesting their potential as diagnostic markers for early detection and disease monitoring [15]. Until now, very few studies have investigated the link between miRNAs and WMLs in the context of neurodegeneration in only small sets of participants [16,17].…”

Section: Introductionmentioning

confidence: 99%

Circulating microRNA miR-425-5p Associated with Brain White Matter Lesions and Inflammatory Processes

Van der Auwera,

Ameling,

Wittfeld

et al. 2024

IJMS

View full text Add to dashboard Cite

White matter lesions (WML) emerge as a consequence of vascular injuries in the brain. While they are commonly observed in aging, associations have been established with neurodegenerative and neurological disorders such as dementia or stroke. Despite substantial research efforts, biological mechanisms are incomplete and biomarkers indicating WMLs are lacking. Utilizing data from the population-based Study of Health in Pomerania (SHIP), our objective was to identify plasma-circulating micro-RNAs (miRNAs) associated with WMLs, thus providing a foundation for a comprehensive biological model and further research. In linear regression models, direct association and moderating factors were analyzed. In 648 individuals, we identified hsa-miR-425-5p as directly associated with WMLs. In subsequent analyses, hsa-miR-425-5p was found to regulate various genes associated with WMLs with particular emphasis on the SH3PXD2A gene. Furthermore, miR-425-5p was found to be involved in immunological processes. In addition, noteworthy miRNAs associated with WMLs were identified, primarily moderated by the factors of sex or smoking status. All identified miRNAs exhibited a strong over-representation in neurodegenerative and neurological diseases. We introduced hsa-miR-425-5p as a promising candidate in WML research probably involved in immunological processes. Mir-425-5p holds the potential as a biomarker of WMLs, shedding light on potential mechanisms and pathways in vascular dementia.

show abstract

The neuroinflammatory role of microRNAs in Alzheimer’s disease: pathological insights to therapeutic potential

Liu,

Rao,

Sun

et al. 2024

Mol Cell Biochem

View full text Add to dashboard Cite

Discerning the Prospects of miRNAs as a Multi-Target Therapeutic and Diagnostic for Alzheimer’s Disease

Cited by 15 publications

References 221 publications

Epigenetic Alterations in Alzheimer’s Disease: Impact on Insulin Signaling and Advanced Drug Delivery Systems

Epigenetic Alterations in Alzheimer’s Disease: Impact on Insulin Signaling and Advanced Drug Delivery Systems

Circulating microRNA miR-425-5p Associated with Brain White Matter Lesions and Inflammatory Processes

The neuroinflammatory role of microRNAs in Alzheimer’s disease: pathological insights to therapeutic potential

Contact Info

Product

Resources

About